1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Drugs In Development, 2022, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 10, 11, 11, 1, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chronic Urticaria Or Hives - Overview
- Chronic Urticaria Or Hives - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chronic Urticaria Or Hives - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
- Chronic Urticaria Or Hives - Drug Profiles
- Chronic Urticaria Or Hives - Dormant Projects
- Chronic Urticaria Or Hives - Discontinued Products
- Chronic Urticaria Or Hives - Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic inducible urticaria
- Jul 03, 2022: Celldex Therapeutics presents positive interim data from barzolvolimab phase 1b study in chronic spontaneous urticaria at EAACI 2022
- Jun 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic spontaneous urticaria
- May 29, 2022: United BioPharma receives TFDA approval for phase 2 IND for UB-221 to treat chronic spontaneous urticaria
- May 19, 2022: Celldex announces acceptance of abstract for barzolvolimab phase 1b results in chronic spontaneous urticaria for late-breaking presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
- Mar 26, 2022: Late-breaking phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis
- Mar 01, 2022: Miravo Healthcare announces the Canadian commercial launch of Blexten for patients 4 years of age and older
- Feb 26, 2022: Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
- Feb 18, 2022: Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program
- Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
- Dec 20, 2021: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
- Dec 01, 2021: Mirae Cell Bio establishes stem cell treatment theory for atopic dermatitis and chronic urticaria
- Nov 30, 2021: Allakos announces expansion of lirentelimab development into atopic dermatitis, chronic spontaneous urticaria and asthma
- Nov 25, 2021: Taiho Pharmaceutical: Announcement of new release of "Vilanoa OD Tablets 20mg" for allergic diseases
- Oct 01, 2021: Novartis’ remibrutinib displays quick disease control in urticaria trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Chronic Urticaria Or Hives, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chronic Urticaria Or Hives - Pipeline by Allakos Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Alvotech ehf, 2022
- Chronic Urticaria Or Hives - Pipeline by Amgen Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by BCN Peptides SA, 2022
- Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, 2022
- Chronic Urticaria Or Hives - Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by CoSci Med-Tech Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Curateq Biologics Pvt Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, 2022
- Chronic Urticaria Or Hives - Pipeline by Genentech USA Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Genu Pharma Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by GSK plc, 2022
- Chronic Urticaria Or Hives - Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by KeifeRx LLC, 2022
- Chronic Urticaria Or Hives - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Leo Pharma AS, 2022
- Chronic Urticaria Or Hives - Pipeline by Luye Pharma Group Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Mirae Cell Bio Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Novartis AG, 2022
- Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by OrchestratePharma GmbH, 2022
- Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Principia Biopharma Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Siolta Therapeutics Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by Third Harmonic Bio Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by Tianchen Biopharmaceutical (Suzhou) Co Ltd, 2022
- Chronic Urticaria Or Hives - Pipeline by TLL Pharmaceutical LLC, 2022
- Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, 2022
- Chronic Urticaria Or Hives - Pipeline by ValenzaBio Inc, 2022
- Chronic Urticaria Or Hives - Dormant Projects, 2022
- Chronic Urticaria Or Hives - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Chronic Urticaria Or Hives, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allakos Inc
- Alvotech ehf
- Amgen Inc
- BCN Peptides SA
- BiosanaPharma BV
- Bioviz Technologies Pvt Ltd
- Celldex Therapeutics Inc
- Celltrion Inc
- CoSci Med-Tech Co Ltd
- Curateq Biologics Pvt Ltd
- DongKoo Bio & Pharma Co Ltd
- Faes Farma SA
- Genentech USA Inc
- Genu Pharma Co Ltd
- GI Innovation Co Ltd
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Inmagene Biopharmaceuticals Ltd
- KeifeRx LLC
- Kiniksa Pharmaceuticals Ltd
- Kyowa Kirin Co Ltd
- Leo Pharma AS
- Luye Pharma Group Ltd
- Mabtech Ltd
- Mirae Cell Bio Co Ltd
- Mycenax Biotech Inc
- Novartis AG
- Oneness Biotech Co Ltd
- OrchestratePharma GmbH
- PharmAbcine Inc
- Principia Biopharma Inc
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Shanghai Pharmaceuticals Holding Co Ltd
- Siolta Therapeutics Inc
- STERO Biotechs Ltd
- Synermore Biologics Co Ltd
- Taiho Pharmaceutical Co Ltd
- Teva Pharmaceutical Industries Ltd
- Third Harmonic Bio Inc
- Tianchen Biopharmaceutical (Suzhou) Co Ltd
- TLL Pharmaceutical LLC
- United Biomedical Inc
- United BioPharma Inc
- ValenzaBio Inc
